{"title":"Roles of MIR155HG and TNF-α in Evaluation of Prognosis of Patients with Systemic Lupus Erythematosus","authors":"Xiaojing Gu, Hu Chen, Rongping Li, Dibin Guo","doi":"10.5937/jomb0-45870","DOIUrl":null,"url":null,"abstract":"Background: To study the roles of micro ribonucleic acid (miR)-155 host gene (MIR155HG) and tumor necrosis factor-α (TNF-α) in the evaluation of prognosis of patients with systemic lupus erythematosus (SLE).
 Methods: A total of 130 patients with SLE admitted to our hospital were selected, and the SLE disease activity index (SLEDAI) score was given. The expressions of MIR155HG and TNF-α were detected via quantitative reverse transcription-polymerase chain reaction (qRT-PCR), the incidence of complications during treatment was observed, and the associations of MIR155HG and TNF-α with SLEDAI before treatment and complications were analyzed. All patients were followed up after discharge, and the related factors to the prognosis of patients were analyzed via Cox regression analysis.
 Results: The levels of MIR155HG and TNF-α were higher in patients with an SLEDAI score of 10-14 points than those in patients with an SLEDAI score of 5-9 points and 0-4 points. MIR155HG and TNF-α were positively correlated with the incidence of infection, renal damage and cardiac damage. Moreover, there was also a positive correlation between the expressions of serum MIR155HG and TNF-α in SLE patients. SLEDAI score ≥10 points, complications during hospitalization, and highly-expressed MIR155HG and TNF-α were risk factors related to the prognosis of patients.
 Conclusion: MIR155HG and TNF-α are key regulators in the pathogenesis of SLE, and they can affect the prognosis of patients. Such a finding provides potential new targets for the treatment of SLE.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"49 2","pages":"0"},"PeriodicalIF":2.0000,"publicationDate":"2023-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/jomb0-45870","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To study the roles of micro ribonucleic acid (miR)-155 host gene (MIR155HG) and tumor necrosis factor-α (TNF-α) in the evaluation of prognosis of patients with systemic lupus erythematosus (SLE).
Methods: A total of 130 patients with SLE admitted to our hospital were selected, and the SLE disease activity index (SLEDAI) score was given. The expressions of MIR155HG and TNF-α were detected via quantitative reverse transcription-polymerase chain reaction (qRT-PCR), the incidence of complications during treatment was observed, and the associations of MIR155HG and TNF-α with SLEDAI before treatment and complications were analyzed. All patients were followed up after discharge, and the related factors to the prognosis of patients were analyzed via Cox regression analysis.
Results: The levels of MIR155HG and TNF-α were higher in patients with an SLEDAI score of 10-14 points than those in patients with an SLEDAI score of 5-9 points and 0-4 points. MIR155HG and TNF-α were positively correlated with the incidence of infection, renal damage and cardiac damage. Moreover, there was also a positive correlation between the expressions of serum MIR155HG and TNF-α in SLE patients. SLEDAI score ≥10 points, complications during hospitalization, and highly-expressed MIR155HG and TNF-α were risk factors related to the prognosis of patients.
Conclusion: MIR155HG and TNF-α are key regulators in the pathogenesis of SLE, and they can affect the prognosis of patients. Such a finding provides potential new targets for the treatment of SLE.
期刊介绍:
The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly.
The Journal publishes original scientific and specialized articles on all aspects of
clinical and medical biochemistry,
molecular medicine,
clinical hematology and coagulation,
clinical immunology and autoimmunity,
clinical microbiology,
virology,
clinical genomics and molecular biology,
genetic epidemiology,
drug measurement,
evaluation of diagnostic markers,
new reagents and laboratory equipment,
reference materials and methods,
reference values,
laboratory organization,
automation,
quality control,
clinical metrology,
all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.